SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic.

Anna Sophie BerghoffMargaretha GanstererArne C BathkeWolfgang TrutschnigPhilipp HungerländerJulia M BergerJudith KremingerAngelika Martina StarzerRobert StrasslRalf SchmidtHarald WillschkeWolfgang LammMarkus RadererAlex D GottliebNorbert J Mauser Matthias Preusser

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Our data indicate that continuation of active anticancer therapy and follow-up visits in a large tertiary care hospital are feasible and safe after implementation of strict population-wide and institutional safety measures during the current COVID-19 pandemic. Routine SARS-CoV-2 testing of patients with cancer seems advisable to detect asymptomatic virus carriers and avoid uncontrolled viral spread.

Keyphrases

sars cov
tertiary care
respiratory syndrome coronavirus
healthcare
primary care
electronic health record
clinical practice
big data
emergency department
stem cells
adverse drug
machine learning
acute care
mesenchymal stem cells
coronavirus disease
bone marrow
deep learning